Mei-Ling Chen, Henning Blume, Gerald Beuerle, Barbara Davit, Mehul Mehta, Henrike Potthast, Barbara Schug, Yu Chung Tsang, Ralph-Steven Wedemeyer, Werner Weitschies, Jan Welink

The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference

European Journal of Pharmaceutical Sciences 111 (2018): 153-157

C. Koch, A. Dax, A. Warnke, L. Pauly, S. Reichart*, E. A. Pestana, J. Stover, K. Lekkos

DISPENSING A HIGH CALORIC, HIGH PROTEIN ORAL NUTRITIONAL SUPPLEMENT 3 TIMES DAILY IS WELL TOLERATED AND INCREASE COMPLIANCE IN ELDERLY

ESPEN 2017

C. Koch, A. Dax, B. Schug, L. Pauly, S. Reichart*, J. Stover, E. A. Pestana, K. Lekkos

NEW HIGH PROTEIN AND HIGH ENERGY ORAL NUTRITIONAL SUPPLEMENT FOR COMPLIANCE AND TOLERANCE IN ELDERLY CARE

ESPEN 2017

Wedemeyer R-S, Blume H

NSAIDs: drug group woth relevant need for galenic improvement

Pharmakon 5 (1): 21-31, 2017

Donath F, Tonner F, Chavda R, Gatignol JP, Bouyrie J

Randomized trial of the efficacy and safety of a new oral spray for drug-induced xerostomia

Clin Exp Dent Res: 1-9, 2016

Jain AK, Söderlind E, Viridén A, Schug BS, Abrahamsson B, Knopke C, Tajarobi F, Blume H, Anschütz M, Welinder A, Richardson S, Nagel S, Abrahmsén-Alami S, Weitschies W

The influence of hydroxypropyl methylcellulose (HPMC) molecular weight, concentration and effect of food on in vivo erosion behavior of HPMC matrix tablets

J Control Release. 187: 50-58, 2014

Jain AK, Viridén A, Welinder A, Schug BS, Abrahmsson B, Knopke C, Söderlind E, Tajarobi F, Blume HH, Anschütz M, Nagel S, Alami Abrahmsén S, Weitschies W

Gastrointestinal erosion behavior of magnetically marked gel matrix tablets

26th AAPS Annual Meeting and Exposition, Chicago, USA, October 14-18, 2012

Schug BS, Donath F, Blume HH

Bioavailability and pharmacodynamics of two 10-mg estradiol valerate depot formulations following i.m. single dose administration in healthy postmenopausal volunteers

Int J Clin Pharmacol Ther. 50 (2): 100-117, 2012

Chen ML, Shah VP, Crommelin DJ, Shargel L, Bashaw D, Bhatti M, Blume HH, Dressman J, Ducharme M, Fackler P, Hyslop T, Lutter L, Morais J, Ormsby E, Thomas S, Tsang YC, Velagapudi R, Yu LX

Harmonization of Regulatory Approaches for Evaluating Therapeutic Equivalence and Interchangeability of Multisource Drug Products: Workshop summary report

Eur J Pharm Sci. 44 (4): 506-513, 2011

Donath F, Braeter M, Feustel C

The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients

Int J Clin Pharmacol Ther. 49 (6): 353-365, 2011

Blume HH, Brendel E, Brudny-Klöppel M, Grebe S, Lausecker B, Rohde G, Siethoff C

Workshop/Conference Report on EMA Draft Guideline on Validation of Bioanalytical Methods

Eur J Pharm Sci. 42 (3): 300-305, 2011

Blume HH, Wedemeyer RS

Austausch von starken Opioiden? – Die therapiäquivalente Arzneimittelqualität muss gewährleistet sein

Dtsch Apoth Ztg. 150 (47): 84-89, 2010

Ruf P, Kluge M, Jäger M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

Br J Clin Pharmacol. 69 (6): 617-625, 2010

Sabatowski R, Grond S, Blume HH

Anforderungen an einer optimierte Opioidtherapie chronischer Schmerzen. Gleichmäßige Plasmaspiegel versus chronoadjustierte Analgesie

MMW Fortschr Med. 152: 12-15, 2010

Blume HH, Wedemeyer RS, Gallwitz B

Bedeutung von GLP-1 für die Glucose-Homöostase

Pharm Unserer Zeit. 39 (2): 100-107, 2010

Stauss-Grabo M, Warnke A, Atiye S, Wedemeyer RS, Blume HH

Investigation of the tolerability and safety of film-coated tablets containing ivy extracts (Prospan ® Cough Tablets) in the treatment of colds accompanied by coughing

58th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Products Research, Berlin, 29th August-2nd September, 2010

Anschütz M, Wonnemann M, Schug BS, Toal C, Donath F, Pontius A, Pauli K, Brendel E, Blume HH

Differences in bioavailability between 60mg of nifedipine osmotic pushpull systems after fasted and fed administration

Int J Clin Pharmacol Ther. 48 (2): 158-170, 2010

Blume HH, Schug BS

Bioavailability/bioequivalence requirements of immediate release products: resolutions and issues

In Bioavailability, Bioequivalence and Pharmacokinetic Studies, K. Midha & T. Nagau, eds., Business Centre for Academic Societies Japan, (2010) pp. 101-106

Grape S, Schug SA, Lauer S, Schug BS

Fentanyl Formulations for the Management of Pain: A Review

Drugs. 70 (1): 57-72, 2010

Kuhn UD, Anschütz M, Schmücker K, Schug BS, Hippius M, Blume HH

Phenotyping with sulfasalazine – time dependence and relation to NAT2 pharmacogenetics

Int J Clin Pharmacol Ther. 48 (1): 1-10, 2010

Anschütz M, Garbacz G, Kosch O, Donath F, Wiedmann J, Hoeckh W, Trahms L, Schug BS, Weitschies W, Blume HH

Characterization of the behavior of alginate-based microcapsules in vitro and in vivo

Int J Clin Pharmacol Ther. 47 (9): 556-563, 2009

Garbacz G., Adam U., Schug BS, Blume HH, Weitschies W

Nifedipin-Retardtabletten mit unterschiedlicher Galenik

Dtsch Apoth Ztg. 149 (27): 3010-3016, 2009

Weitschies W, Blume HH, Mönnikes H

Magnetic Marker Monitoring: High resolution real-time tracking of oral solid dosage forms in the gastroinestinal tract

Eur J Pharm Biopharm. 74 (1): 93-101, 2010

Adam U, Schug BS, Blume HH, Weitschies W

Nifedipin-Retardtabletten mit unterschiedlicher Galenik

Dtsch Apoth Ztg. 149 (27): 3010-3016, 2009

Anschütz M, Flochert F, Donath F, Schug BS, Blume HH

Characterisation of gastric residence time of Provide Xtra DRINK in healty volunteers

30th ESPEN Congress, Florence, September 13-16, 2009

Anschütz M, Garbacz G, Kosch O, Donath F, Wiedmann J, Hoeckh W, Trahms L, Schug BS, Weitschies W, Blume HH

Characterization of the behavior of alginate-based microcapsules in vitro and in vivo

Int J Clin Pharmacol Ther. 47 (9): 556-563, 2009

Warnke A, Schug BS, Vanderbist F, Blume HH

Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources

Int J Clin Pharmacol Ther. 47 (6): 405-412, 2009

Anschütz M, Folchert F, Schug BS, Blume HH, Weitschies W

Characterisation of gastric residence time of ProvideXtra DRINK in healthy volunteers

2008

Blume HH, Ludwig F, Mathis G, Schug BS

GCP-Standards in klinischen Studien mit Medizinprodukten: Chance oder Hindernis?

Medizinprodukte Journal. 15 (3): 148-155, Okt 2008

Kuczka K, Harder S, Picard-Willems B, Warnke A, Donath F, Bianchini P, Parma B, Blume HH

Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight Heparin: Results of a study in healthy subjects with Enoxaparin

J Clin Pharmacol. 48 (10): 1189-1196, 2008

Schug BS, Blume HH

Schneller am Ziel mit Magnetic Marker Monitoring

DZKF. 12 (7-8): 51-56, 2008

Warnke A, Schug BS, Vanderbist F, Blume HH

Importance of the formulation for a chronopharmacologically optimised way of pain therapy. Results of a comparative bioavailability study of tramadol extended-release capsules after single-dose evening versus morning administration

MMW Fortschr Med. 150 (1): 36-42, 2008

Warnke A, Schug BS, Vanderbist F, Blume HH

Bedeutung der Galenik in der »chrono-adjustierten« Schmerzbehandlung.

MMW Fortschr Med. 150 (1): 36-42, 2008

Wonnemann M, Schug BS, Anschütz M, Brendel E, De Nucci G, Blume HH

Comparison of two marketed nifedipine modified-release formulations: An exploratory clinical food interaction study

Clin Ther. 30 (1): 48-58, 2008

Anschütz M, Blume HH, Schug BS, Weitschies W

Gastro-intestinal Transit of Enteric Coated Mesalazine Products: Magnetic Marker Monitoring

CRS 2007 Annual Meeting, Long Beach Convention Center, California, July 7-11, 2007

Nassr N, Lahu G, von Richter O, Reutter F, Knoerzer D, Zech K, Erb KA, Schug BS, Blume HH, Hermann R

Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects

Br J Clin Pharmacol. 63 (3): 365-370, 2007

Richert H, Kosch O, Görnert P

Magnetic Monitoring as a Diagnostic Method for Investigating Motility in the Human Digestive System

in ´Magnetism in Medicine´, a Handbook, edited by Andrä W and Nowak H, Second Edition, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2007

Weinmeister S, Donath F, Anschütz M, Folchert F, Schug BS

Gastrointestinal tolerance of a high-energy oral nutritional supplement (ONS) in healthy elderly and dialysis patients

29th ESPEN Congress on Clinical Nutrition and Metabolism, Prague, September 8-11, 2007

Wonnemann M, Helm I, Stauss-Grabo M, Röttger-Luer P, Tran C-T, Canenbley R, Donath F, Nowak H, Schug BS, Blume HH

Lidocaine 8 mg Sore Throat Lozenges in the Treatment of Acute Pharyngitis

Arzneimittelforschung. 57 (11): 689-697, 2007

Blume HH, Anschütz M, Schmücker K, Schug BS, Haueisen J, Weitschies W

Gastro-intestinal transit of solid oral dosage forms: Imaging studies using Magnetic Marker Monitoring technique

ACCP 2006 Annual Meeting, America´s Center Convention Center, St. Louis, Missouri, October 26–29, 2006

Blume HH, Donath F, Warnke A, Schug BS

Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors

Drug Saf. 29 (9): 769-784, 2006

Haberkorn W, Steinhoff U, Burghoff M, Kosch O, Morguet A, Koch H

Pseudo current density maps of electrophysiological heart, nerve or brain function and their physical basis

Biomagn Res Technol. 4: 5, 2006

Nassr N, Lahu G, von Richter O, Reutter F, Knoerzer D, Zech K, Erb KA, Schug BS, Blume HH, Hermann R

Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects

Br J Clin Pharmacol. 63 (3): 365-370, 2006

Wonnemann M, Schug BS, Schmücker K, Brendel E, van Zwieten PA, Blume HH

Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union

Int J Clin Pharmacol Ther. 44 (1): 38-48, 2006

Blume HH, Schug BS, Tautz J, Erb KA

Neue Richtlinien für die Beurteilung der Bioverfügbarkeit/ Bioäquivalenz

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2005 48: 548-555, 2005

Lehmann G, Folchert F, Schug BS, Anschütz M

Charakterisierung der Magenentleerung einer proteinhydrolysathaltigen, kohlenhydratreichen Trinknahrung im Vergleich zu einer kohlenhydratreichen Referenznahrung

Hauptstadtkongress für Anästhesiologie und Intensivmedizin, Berlin 09.06.-11.06.2005

Migliorança LH, Barrientos-Astigarraga RE, Schug BS, Blume HH, Pereira AS, De Nucci G

Felodipine quantification in human plasma by high performance liquid cromatography coupled to tandem mass spectrometry

J Chromatogr B Analyt Technol Biomed Life Sci. 814 (2): 217-223, 2005

Nassr N, Lahu G, Wolf D, Erb KA, Knoerzer D, Zech K, Wurst W, Hermann R

Lack of pharmacokinetic interaction between roflumilast and midazolam

Eur J Clin Pharamcol. 61 (9): 715, 2005

Warnke A, Blume HH

Wie die Arzneiform zum Therapieerfolg beiträgt – Arzneizubereitungen mit Calciumkanal-Blockern

Pharm Unserer Zeit. 34 (5): 400-410, 2005

Wolf D, Folchert F, Blume HH

Gastric emptying and gastric residual volume after intake of a sip feed containing carbohydrates and protein hydrolysate

27th Congress of the European Society of Clinical Nutrition and Metabolism (ESPEN), Brussels 27.08. - 30.08.2005

Keller JH, Karas M, Müller WE, Volmer DA, Eckert GP, Tawab MA, Blume HH, Dingermann T, Schubert-Zsilavecz M

Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry

Anal Chem. 75 (22): 6084-6088, 2003

Staab A, Schug BS, Larsimont V, Elze M, Thummler D, Mutschler E, Blume HH

Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single doses

Eur J Pharm Sci. 18 (2): 121-128, 2003

Blume HH, Wonnemann M, Wolf HT

NSAR: Konzepte zur galenischen Optimierung

Pharm Unserer Zeit. 31 (2): 170-178, 2002

Blume HH, Schug BS, Brendel E

Sind Nifedipin-Retardpräparate austauschbar?

Dtsch Apoth Ztg. 142 (10): 1192-1204, 2002

Kressmann S, Müller WE, Blume HH

Pharmaceutical quality of different Ginkgo biloba brands

J Pharm Pharmacol. 54 (5): 661-669, 2002

Chen X, Zhong D, Xu H, Schug BS, Blume HH

Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma

J Chromatogr B Analyt Technol Biomed Life Sci. 768 (2): 267-275, 2002

Kaunzinger A, Baumeister A, Cuda K, Haring N, Schug BS, Blume HH, Raddatz K, Fischer G, Schubert-Zsilavecz M

Determination of 11-keto-boswellic acid in human plasma

J Pharm Biomed Anal. 28 (3-4): 729-739, 2002

Kressmann S, Biber A, Wonnemann M, Schug BS, Blume HH, Müller WE

Influence of pharmaceutical quality on the bioavailability of active components form Ginkgo biloba preparations

J Pharm Pharmacol. 54 (11): 1507-1514, 2002

Schug BS, Brendel E, Chantraine E, Wolf D, Martin W, Schall R, Blume HH

The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast

Br J Clin Pharmacol. 53 (6): 582-588, 2002

Schug BS, Brendel E, Wolf D, Wonnemann M, Wargenau M, Blume HH

Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union

Eur J Pharm Sci. 15 (9): 279-285, 2002

Schug BS, Brendel E, Wonnemann M, Wolf D, Wargenau M, Dingler A, Blume HH

Dosage form-related food interaction observed in a marketed one-daily nifedipine formulation after a high-fat American breakfast

Eur J Clin Pharmacol. 58 (2): 119-125, 2002

Blume HH, Wonnemann M, Wolf HT

NSAR: Konzepte zur galenischen Optimierung

Pharm Unserer Zeit. 31 (2): 170-178, 2002

Blume HH, Schug BS, Brendel E

Sind Nifedipin-Retardpräparate austauschbar?

Dtsch Apoth Ztg. 142 (10): 1192-1204, 2002

Blume HH, Cordes H, Klaffenbach P, Schug BS

Qualität von Omeprazol-Präparaten

Dtsch Apoth Ztg. 141 (40): 73-78, 2001

Chen X, Zhong D, Xu H, Schug BS, Blume HH

Simultaneous determination of flupirtine and its major active metabolite in human plasma by liquid chromatography-tandem mass spectrometry

J Chromatogr B Biomed Sci Appl. 755 (1-2): 195-202, 2001

Schug BS, Wolf D, Nilius R, Martin W, Schall R, Blume HH

Product related food effects for nifedipine once daily solid oral dosage forms

Poster at the APV-World Conference. Berlin, 2000

Blume HH, Schug BS

Biopharmaceutical characterisation of herbal medicinal products: are in vivo studies necessary?

Eur J Drug Metab Pharmacokinet. 25 (1): 41-48, 2000

Blume HH, Schug BS

Qualität von Eisenpräparaten

Dtsch Apoth Ztg. 139 (7): 47- 50, 1999

Blume HH, Schug BS

The biopharmaceutics classification system (BCS): class III drugs – better candidates for BA/BE waiver?

Eur J Pharm Sci. 9 (2): 117-121, 1999

Breithaupt-Grogler K, Niebch G, Schneider E, Erb K, Hermann R, Blume HH, Schug BS, Belz GG

Dose-proportionality of oral thioctic acid-coincidence of assessments via pooled plasma and individual data

Eur J Pharm Sci. 8 (1): 57-65, 1999

Gleiter CH, Schreeb KH, Freudenthaler S, Thomas M, Elze M, Fieger-Buschges H, Potthast H, Schneider E, Schug BS, Blume HH, Hermann R

Lack of interaction between thioctic acid, glibenclamide and acarbose

Br J Clin Pharmacol. 48 (6): 819-825, 1999

Heinrich-Nols J, Schug BS, Evers G, Larsimont V, Elze M, Blume HH, Lee LS, Crawford F

Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers

Int J Clin Pharmacol Ther. 37 (3): 153-158, 1999

Mazur D, Schug BS, Evers G, Larsimont V, Fieger-Büschges H, Gimbel W, Keilbach-Bermann A, Blume HH

Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation

Int J Clin Pharmacol Ther. 37 (8): 383-392, 1999

Schug BS, Blume HH

Qualität von Eisenpräparaten – Sind Bioverfügbarkeitsprüfungen erforderlich?

Dtsch Apoth Ztg. 139 (7): 719-722, 1999

Schug BS, Schubert-Zsilavecz M, Blume HH

BCS-Wegweiser bei Phytopharmaka

Loew D, Blume HH, Dingermann T (eds.): Phytopharmaka V, Steinkopff Verlag Darmstadt, 35-42, 1999

Mazur D, Schug BS, Elze M, Blume HH

Klinische Studien 9

Dtsch Apoth Ztg. 138: 3399-3401, 1998

Mazur D, Schug B, Elze M, Blume HH

Klinische Studien 10

138/ (1998) 3658-3661

Mazur D, Schug BS, Evers G, Elze M, Retzow A, Wangemann M, Blume HH

Trough concentrations as parameter for the autoinduction of carbamazepine during repetitive oral administrations

Naunyn Schmiedebergers Arch Pharmacol, 357 (suppl.)/ (1998)

Mazur D, Schug BS, Elze M, Blume HH

Planung, Durchführung und Auswertung klinischer Studien

In Lehrbuch der klinischen Pharmazie, U. Jaehde et al., eds., Wissenschaftliche Verlagsgesellschaft Stuttgart, (1998) pp. 115-137

Schug BS, Hermann R, Blume HH, Elze M

Gender effect on the pharmacokinetics of thioctic acid: an evaluation of several bioavailability studies

Naunyn Schmiedebergers Arch Pharmacol, 357 (suppl.)/ (1998)

Schug BS

Das Biopharmazeutische Klassifizierungssystem BCS – Neuer Ansatz bei der Beurteilung von Arzneimitteln

Dtsch Apoth Ztg. 138 (23): 45-51, 1998

Wangemann M, Retzow A, Evers G, Mazur D, Schug BS, Blume HH

Bioavailability study of two carbamazepine containing sustained release formulations after multiple oral dose administration

Arzneimittelforschung. 48/12 (1998) 1131-1137

Blume HH, Evers G, Elze M, Schug BS, Möhrke W

Absolute Bioavailability of two oral dantrolene formulations

Naunyn Schmiedebergers Arch Pharmacol. 355/ (1997)

Potthast H, Elze M, Fieger-Buschges H, Scheithauer S, Schug BS, Blume HH

Relative bioavailability of etilefrine from different galenical formulations

Naunyn Schmiedebergers Arch Pharmacol. 355/ (1997)

Schug BS, Schneider E, Elze M, Fieger-Buschges H, Larsimont V, Popescu G, Molz K, Blume HH, Hermann R

Study of pharmacokinetic interaction of thioctic acid and metformin

Eur J Clin Pharmacol. 52: 140, 1997

Schug BS, Ruoff J, Schäfer P, Fasold H, Blume HH

Vergleichende Untersuchung von FSH-Produkten

Pharm Ztg. 19: 1570-1575, 1997

Zillig M, Meier J, Scheibe B, Peters F, Schug BS, Blume HH

Zur Qualität von Bluttests in Apotheken

Pharm Ztg. 1666-1671, 1997

Ali S, Blume HH, Schug BS

Sulfonylureas: Physico-chemical properties, analytical methods of determination and bioavailability

In Handbook of Experimental Pharmacology 119, Oral Antidiabetics, J. Kuhlmann & W. Puls, eds., Springer Verlag Berlin, Heidelberg, New York, (1996)

Blume HH, Schug BS

Bioavailability/ Bioeqivalence requirements of immediate release products: resolutions and issues

In Bioavailability, Bioequivalence and Pharmacokinetic Studies, K. Midha & T. Nagai, eds., Business Centre for Academic Societies Japan, (1996) pp. 85-90

Blume HH, Schug BS, Potthast H

Influence of food on the bioavailability of controlled/modified release products, in: Kuhlmann J, Weihrauch TR (eds.).

Eur J Clin Pharmacol. 12: 25-32, 1996

Blume HH, Gundert-Remy U, Schug BS, Elze M, Staab A

Bioverfügbarkeit von Rytmonorm-Importen

Pharm Ztg. 141: 4475-4489, 1996

Schneider E, Gleiter Ch, Schug BS, Elze M, Hermann R, Gundert-Remy U, Blume HH

Influence of food intake on the bioavailability of alpha-lipoic acid.

Eur J Clin Pharmacol. 50 (6): 513-514, 1996

Gleiter CH, Schug BS, Hermann R, Elze M, Blume HH, Gundert-Remy U

Influence of food intake on the bioavailability of thioctic acid enantiomers

Eur J Clin Pharmacol. 50 (6): 513-514, 1996

Larsimont V, Zhong D, Fieger-Buschges H, Schug BS, Staab A, Blume HH

Enantioselective pharmacokinetics and bioavailability of diprafenone in healthy volunteers

Eur J Pharm Sci. 4: 95, 1996

Lipka E, Crison J, Schug BS, Blume HH, Amidon G

Drug interactions in the gastrointestinal tract and their impact on drug absorption and systemic availability: a mechanistic review

In Handbook of experimental pharmacology, Mechanisms of drug interactions, P. D Arcy, J. McElnay, & P. Welling, eds., Springer Verlag Berlin, Heidelberg, New York, (1996) pp. 13-21

Schug BS, Fieger-Buschges H, Elze M, Schneider E, Russ P, Hermann R, Blume HH

Single and multiple dose administration of alpha-lipoic acid in a replicate study design

Eur J Clin Pharmacol. 50: 553, 1996

Schug BS, Elze M, Blume HH

Bioequivalence of highly variable drugs and drug products: steady state studies

In Bioavailability, Bioequivalence and Pharmacokinetic Studies, K. Midha & T. Nagau, eds., Business Centre for Academic Societies Japan, (1996) pp. 101-106

Schug BS, Blume HH

Possibilities and limitations on the interpretation of pharmacokinetic interaction studies (drug-drug, drug-food)

Pharm Unserer Zeit. 25 (4): 195-196, 1996

Blume HH, Elze M, Potthast H, Schug BS

Practical strategies and design advantages in highly variable drug studies: multiple dose and replicate administration design

In Bio-international 2, Bioavailability, Bioequivalence and Pharmacokinetic Studies, H. Blume & K. Midha, eds., medpharm Scientific Publishers Stuttgart, (1995) pp. 117-122

Potthast H, Schug BS, Elze M, Schwerdtle R, Blume HH

Comparison of the bioavailabilities of erythromycin estolate and erythromycin ethylsuccinate dry suspension preparations in steady state

Pharmazie. 50 (1): 56-60, 1995

Potthast H, Schug BS, Blume HH

Vergleich von Erythromycinestolat und Erythromycinethylsuccinat

Sozialpädiatrie und Kinderärztliche Praxis, 17/ (1995) 284-286

Schug BS, Kraemer J, Amels M, Elze M, Fieger-Buschges H, Potthast H, Blume HH

In-vitro und in-vivo-Untersuchungen zu den biopharmazeutischen Eigenschaften zweier Kombinationsanalgetika

In Deutsche Pharmazeutische Gesellschaft.

Schug BS, Kalbhen DA

Influence of chloroquine and other substances on the collagenolytic activity in human osteoarthritic cartilage in vitro

Arzneimittelforschung. 45 (3): 285-289, 1995

Blume HH, Zhong D, Elze M, Wendt G, Schug BS, Scheidel B, Hutt H, Hagenlocher M

Advantages of a steady-state crossover design in assessment of biorquivalence of highly variable drugs: propafenone

Eur J Pharm Sci. 2: 385-393, 1994

Schug BS, Blume HH

Bio International 1994: Wichtige Ergebnisse

Pharm Ztg. 139: 2800-2806, 1994

Schug BS, Kalbhen DA

Human recombinant interleukin-1 alpha and beta and articular tissue integrity. An in vivo study on hens and rats

Arzneimittelforschung. 42 (6): 880-881, 1992

Schug BS, Kalbhen DA

Beeinflussung der Aktivität von Kollagenasen durch verschiedene antirheumatische Wirkstoffe

Pharm Unserer Zeit. 3: 118-119, 1991

Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on page library publications